Tirzepatide · research summary

Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.

Journal of diabetes and metabolic disorders · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Retrospective observational study using real-world data from the TriNetX platform
“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Subjects

Patients with type 2 diabetes using tirzepatide or semaglutide
“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Sample size

271,685 patients in each of two matched cohorts
“two well-matched cohorts (N = 271,685 for each) were analyzed.”

Duration

Data collection period from May 13, 2022 to August 11, 2026
“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Reported findings

Tirzepatide group had lower incidence of the primary composite cardiovascular outcome compared to semaglutide
“Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD − 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84).”
Tirzepatide group had lower incidence of all-cause mortality compared to semaglutide
“Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD − 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84).”

Source: PubMed 42840232 · DOI 10.1007/s40200-026-02087-z · all study summaries

Study type

Retrospective observational study using real-world data from the TriNetX platform

“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Subjects

Patients with type 2 diabetes using tirzepatide or semaglutide

“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Duration

Data collection period from May 13, 2022 to August 11, 2026

“The Research Collaborative Network of the TriNetX platform was accessed to collect de-identified, real world data on patients with T2D and compare the incidence of a composite of cardiovascular outcomes including acute myocardial infarction, stroke and acute heart failure, as well as all-cause mortality between patients who used tirzepatide and patients who used semaglutide during the period May 13, 2022 to Aug 11, 2026.”

Reported findings

Tirzepatide group had lower incidence of the primary composite cardiovascular outcome compared to semaglutide

“Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD − 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84).”

Tirzepatide group had lower incidence of all-cause mortality compared to semaglutide

“Compared to the semaglutide group, the tirzepatide group had lower incidences of the primary composite outcome (4.6% vs. 5.5%; absolute risk difference [ARD] -0.9%, 95% confidence interval [CI] -1.01 to -0.77; hazard ratio [HR] 0.9, 95% CI 0.92─0.96) and all-cause mortality (0.6% vs. 0.9%; ARD − 0.3%, 95% CI -0.33 to -0.24; HR 0.8, 95% CI 0.74─0.84).”